Research programme: diabetes/obesity therapy - Deltagen
Latest Information Update: 01 Sep 2003
At a glance
- Originator Deltagen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 01 Sep 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 01 Sep 2003 No development reported - Preclinical for Obesity in USA (unspecified route)
- 01 Jul 2003 Deltagen has filed a voluntary petition under Chapter 11 of the federal Bankruptcy Code